L. Wagner

发表

Implementation of distress screening in an oncology setting.

F. Penedo, D. Cella, S. Garcia, 2015, The Journal of community and supportive oncology.

Distress Management Clinical Practice Guidelines in Oncology

J. Holland, Deborah A. Freedman-Cass, B. Andersen, 2010 .

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Ingrid A Mayer, 2015, The New England journal of medicine.

A. Abernethy, C. Cleeland, D. Cella, 2010 .

Prospective longitudinal evaluation of a symptom cluster in breast cancer.

J. Beaumont, D. Cella, Z. Butt, 2014, Journal of pain and symptom management.

Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial

R. Gray, G. Sledge, D. Cella, 2021, Cancer.

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.

G. Sica, T. Owonikoko, S. Ramalingam, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)

G. Babiera, T. Julian, G. Sledge, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SOAPP (Symptom Outcomes and Practice Patterns): A Survey of Disease and Treatment-Related Symptoms in Patients with Invasive Cancer of the Breast, Prostate, Lung or Colon/Rectum

J. Manola, C. Cleeland, M. Fisch, 2006 .

Cancer‐related fatigue

A. Abernethy, C. Cleeland, D. Cella, 2010, Cancer.

Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns

Joel L. Voss, F. Penedo, D. Cella, 2017, NeuroImage: Clinical.

Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients: An Analysis from the Symptom Outcomes and Practice Patterns (SOAPP) Study

J. Schiller, H. Hamann, M. Fisch, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry

J. Hardin, S. Jagannath, R. Rifkin, 2021, Blood cancer journal.

Connect MM Registry as a national reference for United States multiple myeloma patients

J. Hardin, S. Jagannath, A. Agarwal, 2019, Cancer medicine.

The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)

D. Cella, M. Lacouture, L. Wagner, 2013, Supportive Care in Cancer.

Quality of life and psychosocial issues

D. Cella, L. Wagner, 2006 .

Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape

Benjamin J. Keele, A. Benson, R. Carlos, 2019, Cancer.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

C. Chung, A. Cmelak, R. Ferris, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

R. Fonseca, S. Lonial, M. Dhodapkar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).

C. Chung, A. Cmelak, R. Ferris, 2012 .

E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).

C. Chung, R. Ferris, W. Westra, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and validation of the functional assessment of cancer therapy–antiangiogenesis subscale

J. Beaumont, D. Cella, S. Yount, 2015, Cancer medicine.

Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer

G. Sledge, R. Carlos, K. Miller, 2020, Cancer medicine.

Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery.

W. Gradishar, B. Rapkin, I. Gareen, 2016, Journal of oncology practice.

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

R. Gascoyne, T. Habermann, J. Krauss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptom burden among young adults with breast or colorectal cancer

M. Fisch, J. Salsman, L. Wagner, 2014, Cancer.

Recommendations for the implementation of distress screening programs in cancer centers: Report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force

J. Holland, W. Bardwell, J. Greer, 2014, Cancer.

Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.

R. Gray, T. Whelan, G. Sledge, 2021, JAMA oncology.

Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary.

I. Gareen, S. Parsons, J. Salsman, 2022, JCO precision oncology.

Longitudinal prospective assessment of sleep quality: before, during, and after adjuvant chemotherapy for breast cancer

J. Beaumont, D. Cella, Z. Butt, 2013, Supportive Care in Cancer.

Simulating Colorectal Cancer Trials Using Real-World Data.

Thomas J. George, Hansi Zhang, Yi Guo, 2022, JCO clinical cancer informatics.

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

J. Hardin, S. Jagannath, S. Srinivasan, 2019, British journal of haematology.

Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.

J. Hardin, S. Jagannath, S. Srinivasan, 2021, Clinical lymphoma, myeloma & leukemia.

C. Cleeland, D. Cella, H. Rugo, 2015 .

Re-personalizing precision medicine: is there a role for patient-reported outcomes?

D. Cella, L. Wagner, 2015 .

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)

K. Flaherty, A. Onitilo, I. Gareen, 2021, Cancer.

Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]

D. Levy, I. Gareen, J. Sicks, 2022, BMC Public Health.

Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.

J. Hardin, S. Jagannath, S. Srinivasan, 2019, Clinical lymphoma, myeloma & leukemia.

Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.

J. Manola, K. Flaherty, M. Atkins, 2015 .

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805

J. Manola, D. Cella, R. DiPaola, 2018, Quality of Life Research.

Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.

J. Cashy, D. Cella, S. Yount, 2007, Journal of the National Cancer Institute. Monographs.

Should Health-Related Quality of Life Be Measured in Cancer Symptom Management Clinical Trials? Lessons Learned Using the Functional 53

L. Minasian, J. Cashy, D. Cella, 2007 .

Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care

David Cella, Frank J Penedo, Richard Gershon, 2015, Cancer.

A new quality standard: the integration of psychosocial care into routine cancer care.

P. Jacobsen, L. Wagner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (E1A11): a multicenter, open label, phase 3, randomized, controlled trial

Prashant, P. Richardson, N. Callander, 2020 .

A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201

A. Benson, S. Alberts, H. Cárdenes, 2008 .

A. Abernethy, F. M. Stewart, P. Hinds, 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

R. Advani, R. Gascoyne, T. Habermann, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Lynne Wagner, Dennis P. West, Ethan Basch, 2010, Supportive Care in Cancer.

Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.

M. Lacouture, L. Wagner, 2007, Oncology.

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging

Linda K. Han, C. Gatsonis, C. Lehman, 2022, JAMA network open.

Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial).

Linda K. Han, C. Lehman, A. Wolff, 2021, Radiology.

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

R. Gray, D. Cella, I. Gareen, 2021, Cancer.

E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (QOL) analysis.

D. Cella, A. Benson, S. Alberts, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

R. Gascoyne, J. Krauss, S. Horning, 2011 .

A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth intervention

Daniel L. Hall, D. Mohr, W. Gradishar, 2022, Journal of Behavioral Medicine.

“I need more knowledge”: Qualitative analysis of oncology providers’ experiences with sexual and gender minority patients

M. Schabath, G. Quinn, R. Carlos, 2022, Frontiers in Psychology.

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients

R. Gray, D. Cella, Shaji K. Kumar, 2022, Blood Cancer Journal.

Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment.

J. Yeboah, D. Herrington, G. Lesser, 2022, NEJM evidence.

Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline

E. Bruera, K. Ramchandran, Nofisat Ismaila, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry

J. Hardin, S. Jagannath, R. Rifkin, 2019, Blood Cancer Journal.

Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials.

P. Hinds, D. Cella, P. Ganz, 2022, Journal of the National Cancer Institute.

Curing Hodgkin's lymphoma: quantity and quality.

A. Evens, L. Wagner, 2009, The Lancet. Oncology.

S6-2: Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole.

G. Sledge, D. Cella, P. Goss, 2011 .

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

S. Signoretti, B. Leibovich, T. Choueiri, 2019, Future oncology.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Blood advances.

Reply to T. Shimoi et al and Y. Shimanuki et al.

W. Symmans, A. Wolff, A. DeMichele, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trajectory of cognitive impairment during breast cancer treatment: A prospective analysis.

J. Beaumont, D. Cella, Z. Butt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?

D. Cella, E. Ip, S. Shaunfield, 2022, Supportive Care in Cancer.

Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.

S. Jagannath, K. Ramasamy, R. Rifkin, 2022, Clinical lymphoma, myeloma & leukemia.

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

W. Symmans, A. Wolff, A. DeMichele, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatigue and cancer: causes, prevalence and treatment approaches

D. Cella, L. Wagner, D. Cella, 2004, British Journal of Cancer.

Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis.

Lorie A. Kloda, J. Ioannidis, P. Cuijpers, 2020, Journal of clinical epidemiology.

Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy

R. Gray, J. Sparano, N. Davidson, 2013, Cancer.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

J. Manola, K. Flaherty, T. Choueiri, 2016, The Lancet.

Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2018, The New England journal of medicine.

Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.

J. Olson, M. Ellis, R. Gray, 2020, Journal of the National Cancer Institute.

Biomarker testing in non-small cell lung cancer (NSCLC): An assessment of current practices in precision oncology in the community setting—A trial of the ECOG-ACRIN cancer research group (EAQ161CD).

B. Rapkin, J. Sicks, K. Weaver, 2021 .

Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center

V. Thorsson, M. Nykter, I. Shmulevich, 2017, Theranostics.

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

David Cella, Lynne Wagner, Christopher H Crane, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.

I. Tannock, S. Alibhai, F. Joly, 2006, The Journal of urology.

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

J. Manola, D. Cella, R. DiPaola, 2018, Supportive Care in Cancer.

Cancer-Related Fatigue, Version 2.2015.

David Cella, Thomas LeBlanc, Oxana Palesh, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Measuring Quality of Life in Cancer Survivors

D. Cella, M. Smith, David E Victorson, 2007 .

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

S. Lonial, P. Richardson, Shaji K. Kumar, 2020, The Lancet. Oncology.

Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma

A. Benson, A. Barbault, B. Pasche, 2021, 4open.

Distress management.

J. Holland, B. Andersen, P. Jacobsen, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Employment outcomes among survivors of common cancers: the Symptom Outcomes and Practice Patterns (SOAPP) study

J. Manola, C. Cleeland, K. Buhr, 2013, Journal of Cancer Survivorship.

A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).

G. Babiera, T. Julian, G. Sledge, 2020 .

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2019, The New England journal of medicine.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

J. Olson, M. Ellis, R. Gray, 2020, JAMA oncology.

Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ

C. Gatsonis, C. Lehman, I. Gareen, 2021, JAMA network open.

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.

J. Olson, R. Gray, W. McCaskill-Stevens, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains

Lisa G. Smith, G. Sledge, D. Cella, 2014, Cancer.

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

D. Cella, Molin Wang, K. Miller, 2011, Breast Cancer Research and Treatment.

Patient perspectives on chemotherapy de‐escalation in breast cancer

A. Wolff, A. DeMichele, N. Tung, 2021, Cancer medicine.

Heterogeneity of Second‐Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010–2016)

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Clinical lymphoma, myeloma & leukemia.

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.

S. Martino, N. Robert, D. Cella, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determinants of pain severity changes in ambulatory patients with cancer: an analysis from Eastern Cooperative Oncology Group trial E2Z02.

Fengmin Zhao, C. Cleeland, J. Cleary, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

E. V. Van Allen, S. Signoretti, T. Choueiri, 2019 .

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).

P. Catalano, N. Petrelli, J. Sloan, 2019, The oncologist.

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

R. Gray, T. Shanafelt, D. Cella, 2020 .

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

T. Whelan, G. Sledge, D. Cella, 2018, Breast Cancer Research and Treatment.

Validation of the FACT-BRM with interferon-alpha treated melanoma patients.

B. Redman, L. Wagner, P. Trask, 2005, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.

Validation of the FACT-BRM with interferon-α treated melanoma patients

B. Redman, L. Wagner, P. Trask, 2005, Quality of Life Research.

Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future

D. R. Lewis, A. Geiger, Ashley Wilder Smith, 2016, Cancer.

Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients.

P. Jacobsen, C. Anasetti, L. Wagner, 2007, Journal of pain and symptom management.

Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction.

R. Fonseca, D. Cella, D. Robinson, 2012, Journal of pain and symptom management.

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Annals of Hematology.

Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Clinical therapeutics.

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

S. Lonial, M. Dhodapkar, Robert A Emmons, 2019, Journal of Clinical Oncology.

Factors Influencing Cognitive Function, Sleep, and Quality of Life in Individuals With Systemic Lupus Erythematosus: A Review of the Literature

P. Zee, N. Doninger, L. Wagner, 2004, The Clinical neuropsychologist.

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

J. Hardin, S. Jagannath, A. Agarwal, 2020, Cancer.

Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.

J. Hardin, S. Jagannath, S. Srinivasan, 2017 .

Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results

R. Gray, W. McCaskill-Stevens, T. Whelan, 2019, General Session Abstracts.

Adaptation of a Personalized Electronic Care Planning Tool for Cancer Follow-up Care: Formative Study

U. Topaloglu, B. Pasche, David P. Miller, 2022, JMIR formative research.

Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions.

E. Shaw, D. Cella, L. Wenzel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy–Neutropenia (FACT-N)

J. Beaumont, D. Cella, A. Peterman, 2007, Supportive Care in Cancer.

Reduced prefrontal activation during working and long‐term memory tasks and impaired patient‐reported cognition among cancer survivors postchemotherapy compared with healthy controls

Lei Wang, Joel L. Voss, David Cella, 2016, Cancer.

Physical Activity During Breast Cancer Therapy Associates With Preserved Exercise Capacity and Cardiac Function (WF97415)

W. Hundley, N. Avis, J. Canada, 2023, JACC. CardioOncology.

Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.

D. Kent, G. Sledge, B. Ky, 2019, Clinical breast cancer.

Evaluating the dimensionality of perceived cognitive function.

J. Beaumont, D. Cella, J. Lai, 2009, Journal of pain and symptom management.

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

R. Gascoyne, T. Habermann, J. Krauss, 2016, British journal of haematology.

Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy

J. V. Von Roenn, J. Beaumont, D. Cella, 2008, Supportive Care in Cancer.

The Management of Fatigue in Cancer Patients

D. Cella, L. Wagner, 2004 .

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2018, npj Breast Cancer.

Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach.

Christoph I. Lee, E. Pisano, I. Gareen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-step Approach to Adapting a Mind-Body Resiliency Intervention for Fear of Cancer Recurrence and Uncertainty in Survivorship (IN FOCUS)

Daniel L. Hall, E. Park, J. Peppercorn, 2022, Global advances in health and medicine.

The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.

C. Cleeland, T. Mendoza, L. Patrick-Miller, 2013, Clinical breast cancer.

Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial.

R. Gray, T. Whelan, G. Sledge, 2022, JAMA oncology.

Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient‐reported outcomes substudy

R. Gray, T. Whelan, G. Sledge, 2021, Cancer.

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

C. Moinpour, M. Lacouture, A. Barzi, 2020, Journal of Patient-Reported Outcomes.

Using the science of psychosocial care to implement the new american college of surgeons commission on cancer distress screening standard.

D. Spiegel, T. Pearman, L. Wagner, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.

J. Manola, W. McCaskill-Stevens, L. Minasian, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2017, npj Breast Cancer.

Cancer Survivorship Care for Adult Survivors of Childhood Cancer: An Adult Based Model Facilitating Multi-Disciplinary Long-Term Follow-Up Care, Education and Research

A. Didwania, K. Kinahan, T. Pearman, 2013 .

Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health‐Related Quality of Life, and Special Considerations in Dermatologic Oncology

D. Cella, L. Wagner, 2013 .

R. Rothman, J. Tooze, N. Avis, 2023, Supportive Care in Cancer.

NCCN Clinical Practice Guidelines Cancer-related fatigue.

A. Abernethy, C. Cleeland, D. Cella, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy.

C. Cleeland, M. Fisch, X. Wang, 2020, JCO oncology practice.

Self‐reported cognitive concerns and abilities: two sides of one coin?

D. Cella, J. Lai, P. Jacobsen, 2014, Psycho-oncology.

Distress Screening for Oncology Patients

W. Pirl, L. Wagner, J. Fann, 2014 .

Implementing screening for distress: the joint position statement from the American Psychosocial Oncology Society, Association of Oncology Social Work, and Oncology Nursing Society.

J. Holland, W. Bardwell, J. Greer, 2013, Oncology nursing forum.

Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice.

David Cella, Jennifer L Beaumont, J. V. Von Roenn, 2008, Journal of pain and symptom management.

Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial

Daniel L. Hall, D. Mohr, W. Gradishar, 2021, Journal of the National Cancer Institute.

Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates

A. Wolff, K. Wiseman, L. Wagner, 2022, BMC cancer.

Assessing cognitive function in cancer patients

I. Tannock, P. Maruff, J. Vardy, 2006, Supportive Care in Cancer.

Implementing electronic health record–integrated screening of patient‐reported symptoms and supportive care needs in a comprehensive cancer center

David Cella, Katy Wortman, Frank J Penedo, 2019, Cancer.

Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy

Joel L. Voss, Matthew P. Schroeder, F. Penedo, 2018, NeuroImage: Clinical.

The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group.

C. Cleeland, T. Mendoza, L. Patrick-Miller, 2014, Clinical genitourinary cancer.

Coping Among Breast Cancer Survivors: A Confirmatory Factor Analysis of the Brief COPE

V. Champion, P. Monahan, K. Rand, 2019, Journal of Nursing Measurement.

Development of an eHealth System to Capture and Analyze Patient Sensor and Self-Report Data: Mixed-Methods Assessment of Potential Applications to Improve Cancer Care Delivery

Jason Nawyn, N. Rothrock, F. Albinali, 2018, JMIR medical informatics.

Symptom burden and change among adolescent/young adult (AYA) patients with breast, lung, colorectal, or prostate cancer.

M. Fisch, J. Salsman, L. Wagner, 2011, Journal of Clinical Oncology.

Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden.

A. Rademaker, J. Raizer, I. Helenowski, 2014, Neuro-oncology practice.

Coping strategies tailored to the management of fear of recurrence and adaptation for E‐health delivery: The FoRtitude intervention

David Cella, David C Mohr, Jenna Duffecy, 2017, Cancer.

Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

A. Benson, J. Sparano, C. Loprinzi, 2021 .

French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3

J. Beaumont, F. Joly, O. Rigal, 2012, Supportive Care in Cancer.

ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation.

Shaji K. Kumar, S. Rajkumar, L. Kostakoglu, 2021 .

Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall QoL domains

Lisa G. Smith, G. Sledge, D. Cella, 2014 .

Association between an electronic health record (EHR)–embedded frailty index and survival among older adults receiving cancer chemotherapy.

U. Topaloglu, J. Tooze, N. Pajewski, 2022, Journal of Clinical Oncology.

Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial

W. Small, B. Tran, D. Bruner, 2017, Cancer.

Comparison of different scoring methods based on latent variable models of the PHQ-9: an individual participant data meta-analysis

Lorie A. Kloda, Carl F. Falk, J. Ioannidis, 2021, Psychological Medicine.

A randomized controlled pilot study of Yoga Skills Training versus an attention control delivered during chemotherapy administration.

B. Nicklas, R. Rothman, J. Tooze, 2021, Journal of pain and symptom management.

Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors

J. Manola, W. Pirl, M. Fisch, 2015, Psycho-oncology.

Measurement and management of health-related quality of life in lung cancer.

D. Cella, S. Yount, L. Wagner, 2004, Clinical advances in hematology & oncology : H&O.

Randomized clinical trial to evaluate an e-health intervention for fear of cancer recurrence, anxiety, and depression among cancer survivors.

D. Mohr, K. Lehman, M. Begale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-Reported Outcomes Bridge an Important Gap in Identifying Risk for Early Endocrine Therapy Discontinuation.

L. Wagner, 2021, Journal of the National Cancer Institute.

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

R. Fonseca, D. Cella, L. Wagner, 2011 .

Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials

L. Wagner, G. Rocque, L. Wallner, 2022, The oncologist.

Social determinants of health, genetic ancestry, and mortality in ECOG-ACRIN E5103.

G. Sledge, A. Partridge, R. Carlos, 2021, Journal of Clinical Oncology.

Physicians’ Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care

L. Wagner, G. Rocque, L. Wallner, 2023, The oncologist.

E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).

C. Chung, A. Cmelak, R. Ferris, 2013 .

Screening for depression in community-based radiation oncology settings: Results from RTOG 0841.

W. Small, B. Tran, D. Bruner, 2013 .

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

S. Lonial, P. Richardson, Shaji K. Kumar, 2020, Journal of Clinical Oncology.

Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.

K. Nephew, G. Fulci, D. Cella, 2023, Gynecologic oncology.

Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

D. Cella, T. Owonikoko, S. Ramalingam, 2020, Cancer medicine.

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).

R. Advani, R. Gascoyne, T. Habermann, 2016 .

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

J. Hardin, S. Jagannath, S. Srinivasan, 2017 .

Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment

N. Tung, L. Wagner, G. Rocque, 2022, JCO oncology practice.

Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2015 .

Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI

M. Lacouture, P. LoRusso, R. Perez-soler, 2007 .

Development and refinement of FoRtitude: An eHealth intervention to reduce fear of recurrence among breast cancer survivors

D. Mohr, F. Penedo, D. Cella, 2019, Psycho-oncology.

Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash

A. Rademaker, D. West, M. Lacouture, 2008 .

Assessing neurocognitive symptoms in cancer patients and controls: psychometric properties of the FACT-Cog3

H. Green, L. Wagner, Vibeke Koch, 2021, Current Psychology.

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

J. Hardin, S. Jagannath, S. Srinivasan, 2020, British journal of haematology.

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

J. Friedberg, J. Leonard, N. Bartlett, 2021 .

Abstract OT2-01-04: E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

R. Gray, J. Sparano, A. Tevaarwerk, 2016 .

Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.

Linda K. Han, C. Gatsonis, W. McCaskill-Stevens, 2019, JAMA oncology.

Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal

B. Ky, J. Carver, C. Denlinger, 2019, Clinical colorectal cancer.

Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805.

D. Cella, R. DiPaola, B. Ky, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105).

Ximing J. Yang, E. Perez, G. Sledge, 2012 .

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

J. Olson, M. Ellis, R. Gray, 2015, The New England journal of medicine.

Self‐reported cognitive concerns and abilities: two sides of one coin?

D. Cella, J. Lai, P. Jacobsen, 2014, Psycho-oncology.

J. Holland, W. Bardwell, J. Greer, 2014, Cancer.

Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805

J. Manola, D. Cella, R. DiPaola, 2018, Quality of Life Research.

Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).

G. Weinstein, R. Ferris, R. Mehra, 2021 .

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry

J. Hardin, S. Jagannath, R. Rifkin, 2020, Blood.

Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates

J. Olson, R. Gray, T. Whelan, 2023, Cancer Research.

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

J. Manola, D. Cella, R. DiPaola, 2018, Supportive Care in Cancer.

Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients: An Analysis from the Symptom Outcomes and Practice Patterns (SOAPP) Study

J. Schiller, H. Hamann, M. Fisch, 2013, Journal of Thoracic Oncology.

Psychological Treatment for Patients Receiving Radiation: Results of NRG Oncology/RTOG 0841.

W. Small, B. Tran, D. Bruner, 2021, International journal of radiation oncology, biology, physics.

Heterogeneity of Second‐Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010–2016)

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Clinical lymphoma, myeloma & leukemia.